Clinical Trial Update: PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AmBisome as primary antifungal prophylaxis in high-risk allogeneic stem cell transplant patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fungal Infections

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)

Snippet

Sponsor: Gilead Sciences | Conditions: Fungus Diseases | Phase 2 | Status: COMPLETED